Abstract:Christophe Mallet, 1 Jules Desmeules, 2 Rassa Pegahi, 3 Alain Eschalier 1 1 Université Clermont Auvergne, INSERM, NEURO-DOL Basics & Clinical Pharmacology of Pain, Clermont-Ferrand, France; 2 Faculty of Medicine and The School of Pharmaceutical Sciences, Faculty of Sciences, Geneva University, Geneva, Switzerland; 3 Medical Affairs Department, UPSA, Paris, France Correspondence: Alain Eschalier, Faculté de Médecine, UMR Neuro-Dol, 49 Bd François Mitterrand, Clermont-Ferrand, 63000, France, Email Paracetamol remains the recommended first-line option for mild-to-moderate acute pain in general population and particularly in vulnerable populations. Despite its wide use, debate exists regarding the analgesic mechanism of action (MoA) of paracetamol. A growing body of evidence challenged the notion that paracetamol exerts its analgesic effect through cyclooxygenase (COX)-dependent inhibitory effect. It is now more evident that paracetamol analgesia has multiple pathways and is mediated by the formation of the bioactive AM404 metabolite in the central nervous system (CNS). AM404 is a potent activator of TRPV 1 , a major contributor to neuronal response to pain in the brain and dorsal horn. In the periaqueductal grey, the bioactive metabolite AM404 activated the TRPV 1 channel‐mGlu5 receptor‐PLC‐DAGL‐CB1 receptor signaling cascade. The present article provides a comprehensive literature review of the centrally located, COX-independent, analgesic MoA of paracetamol and relates how the current experimental evidence can be translated into clinical practice. The evidence discussed in this review established paracetamol as a central, COX-independent, antinociceptive medication that has a distinct MoA from non-steroidal anti-inflammatory drugs (NSAIDs) and a more tolerable safety profile. With the establishment of the central MoA of paracetamol, we believe that paracetamol remains the preferred first-line option for mild-to-moderate acute pain for healthy adults, children, and patients with health concerns. However, safety concerns remain with the high dose of paracetamol due to the NAPQI-mediated liver necrosis. Centrally acting paracetamol/ p -aminophenol derivatives could potentiate the analgesic effect of paracetamol without increasing the risk of hepatoxicity. Moreover, the specific central MoA of paracetamol allows its combination with other analgesics, including NSAIDs, with a different MoA. Future experiments to better explain the central actions of paracetamol could pave the way for discovering new central analgesics with a better benefit-to-risk ratio. Keywords: paracetamol, acetaminophen, AM404, analgesia, molecular targets The mechanisms of how paracetamol works are still subject to debate despite its widespread use. Previous scientific research questions the idea that paracetamol relieves pain by inhibiting cyclooxygenases (COX). Now, it is more apparent that paracetamol's pain-relieving effect occurs in the brain and is independent of the COX enzyme. This article reviewed the central paracetamol actions and how the current experimental evidence can be used in clinical practice. Based on the evidence discussed in this review, paracetamol works differently than NSAIDs and has a safer safety profile. With the central MoA for paracetamol in place, we think paracetamol will still be the first choice for acute pain management. When the COX-independent mechanism of action and stable pharmacokinetic properties of paracetamol are considered, it is safe to say that paracetamol should be preferred over NSAIDs for analgesia, especially in special populations. Newer painkillers, based on the central action of paracetamol, are being studied and show promising results in relieving pain without increasing the risk of liver damage. Pain represents substantial healthcare and financial burden despite the available pain management approaches, highlighting the urgent need for innovative medications and, possibly, indications of established analgesics. 1 Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (also known as acetaminophen or N -acetyl- p -aminophenol) are commonly prescribed for pain management in a wide range of conditions. Globally, paracetamol is also at the apex of the most commonly utilized over-the-counter (OTC) analgesic and the preferred first-line option for patients with mild-to-moderate acute pain. 2 The good tolerability at the recommended dosage (eg, lack of gastrointestinal adverse effects) is a major contributor to the preference for paracetamol by general practitioners, specialists, and pharmacists. 3 Although it was introduced in clinics more than 100 years ago, 4 paracetamol remains the recommended first-line option for pain ma -Abstract Truncated-

Exploring acetaminophen prodrugs and hybrids: a review

Analgesic Prodrugs for Combating their Side-Effects: Rational Approach

Synthesis and Pharmacological Evaluation of New Chemical Entities Based on Paracetamol and Their Ibuprofen Conjugates as Novel and Superior Analgesic and Anti-Inflammatory Candidates

Acetaminophen: Ancient drug with a novel analgesic mechanism of action

Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action

Parenteral Ready-to-Use Fixed-Dose Combinations Including NSAIDs with Paracetamol or Metamizole for Multimodal Analgesia-Approved Products and Challenges

Synthetic Strategies Towards Safer NSAIDs Through Prodrug Approach: A Review

Prodrug Rewards in Medicinal Chemistry: An Advance and Challenges Approach for Drug Designing

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

Anti-Inflammatory and Anticoagulant Activities of Synthesized NSAID Prodrug Esters

[Paracetamol: a promising ancestor]

An Updated Review on the Metabolite (AM404)-Mediated Central Mechanism of Action of Paracetamol (Acetaminophen): Experimental Evidence and Potential Clinical Impact

Paracetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug

Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics

Opioid analgesia: recent developments

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

Analgesic Activity of 5-Acetamido-2-Hydroxy Benzoic Acid Derivatives and an In-Vivo and In-Silico Analysis of Their Target Interactions

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects

Design, Synthesis, Chemical Characterization and In-vivo Screening of Prodrugs

Acetaminophen: for Its Mechanism of Analgesic Action in Vivo Using Molecular Docking

Morphinan Evolution: The Impact of Advances in Biochemistry and Molecular Biology